Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study-Reference-Cited by-同舟云学术

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Published:2021-03-16 Issue:4 Volume:22 Page:581-586
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Patruno Cataldo,Fabbrocini Gabriella,Longo Giuseppe,Argenziano Giuseppe,Ferrucci Silvia Mariel,Stingeni Luca,Peris Ketty,Ortoncelli Michela,Offidani Annamaria,Amoruso Giuseppe Fabrizio,Talamonti Marina,Girolomoni Giampiero,Grieco Teresa,Iannone Michela,Nettis Eustachio,Foti Caterina,Rongioletti Franco,Corazza Monica,Veneri Michele Delli,Napolitano Maddalena^ORCID,Angileri L,Bianchelli T,Borghi A,Calabrese G,Chello C,Dal Bello G,Dastoli S,Ferrillo M,Galluzzo M,Gori N,Hansel K,Macchia L,Piras V,Provenzano E,Ribero S,Romanelli M,Romita P,

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-021-00597-5.pdf

Reference10 articles.

1. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–303.

2. Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:131–43.

3. Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181:1072–4.

4. Ruiz-Villaverde R, Dominguez-Cruz J, Armario-Hita JC, Martinez-Pilar L, Alcantara-Luna S, Pereyra- Rodriguez JJ. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series. Dermatol Ther. 2019;32:e12931.

5. Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82:1530–2.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Remission of Severe and Refractory Chronic Actinic Dermatosis with Dupilumab: A Case Report with Review of the Literature;Acta Dermato-Venereologica;2024-08-23

2. Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?;Journal of Personalized Medicine;2024-07-22

3. Long-term Efficacy of Dupilumab in Papulo-erythroderma of Ofuji;Acta Dermato-Venereologica;2024-06-07

4. Atopic dermatitis: treatment and innovations in immunotherapy;Inflammopharmacology;2024-04-06

5. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT;Advances in Therapy;2024-03-05